Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Sep 13;39(9):1279-1291.e3.
doi: 10.1016/j.ccell.2021.07.005. Epub 2021 Aug 12.

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Qing Zhou  1 , Chong-Rui Xu  1 , Ying Cheng  2 , Yun-Peng Liu  3 , Gong-Yan Chen  4 , Jiu-Wei Cui  5 , Nong Yang  6 , Yong Song  7 , Xiao-Ling Li  8 , Shun Lu  9 , Jian-Ying Zhou  10 , Zhi-Yong Ma  11 , Shi-Ying Yu  12 , Cheng Huang  13 , Yong-Qian Shu  14 , Zhen Wang  1 , Jin-Ji Yang  1 , Hai-Yan Tu  1 , Wen-Zhao Zhong  1 , Yi-Long Wu  15
Affiliations
Clinical Trial

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Qing Zhou et al. Cancer Cell. .

Abstract

Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung cancer (NSCLC). This phase 3 study investigated the efficacy and safety of an erlotinib plus bevacizumab regimen in untreated patients with advanced NSCLC. In total, 311 patients received bevacizumab plus erlotinib (n = 157) or erlotinib only (n = 154). Progression-free survival (PFS) was 17.9 months (95% confidence interval [CI], 15.2-19.9) for bevacizumab plus erlotinib and 11.2 months (95% CI, 9.7-13.8) for erlotinib only (hazard ratio [HR] = 0.55; 95% CI, 0.41-0.73; p < 0.001). A brain metastases subgroup treated with bevacizumab plus erlotinib also showed improved PFS (HR = 0.48; 95% CI, 0.27-0.84; p = 0.008). Grade ≥3 treatment-related adverse events occurred in 86 (54.8%) and 40 (26.1%) patients, respectively. Bevacizumab plus erlotinib significantly improved PFS in patients with untreated metastatic EGFR-mutated NSCLC, including those with brain metastases at baseline.

Keywords: EGFR mutation; bevacizumab; epidermal growth factor receptor inhibitor; erlotinib; non-small cell lung cancer; vascular endothelial growth factor inhibitor.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Y.-L.W. reports advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, Takeda; personal fees from AstraZeneca, Beigene, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi; grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, and Roche, outside the submitted work. Q.Z. reports honoraria from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi, outside the submitted work. W.-Z.Z. reports honoraria from AstraZeneca, Eli Lilly, Pfizer, Roche, and Sanofi, outside the submitted work. All other authors declare no competing interests.

Comment in

Publication types

MeSH terms

LinkOut - more resources